Inpatient Growth in Infants Requiring Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome

Ashajyothi M Siddappa1,2, Erin Morris3, Michael D Evans4

  • 1Neonatology Department of Pediatrics Hennepin Healthcare, Minneapolis, Minnesota, USA.

PubMed

Insights

Infants with neonatal opioid withdrawal syndrome (NOWS) requiring treatment show decreased growth parameters. Polysubstance exposure is linked to poorer inpatient growth, while short-acting opioid exposure may improve it.

Area of Science:

  • Neonatal care
  • Pediatric growth and development
  • Pharmacology

Background:

  • Neonatal Opioid Withdrawal Syndrome (NOWS) affects infants exposed to opioids prenatally.
  • Growth parameters are critical indicators of infant health and development.
  • Understanding factors influencing growth in NOWS infants is essential for optimizing care.

Purpose of the Study:

  • To assess inpatient growth parameter trajectories in infants treated for NOWS.
  • To identify the influence of prenatal opioid exposure type and treatment characteristics on infant growth.
  • To analyze growth patterns based on opioid exposure (short-acting, long-acting, polysubstance), treatment, and sex.

Main Methods:

  • Retrospective chart review of term infants with NOWS admitted to the NICU (2012-2019).
  • Analysis of intake (volume, calories) and growth parameters (weight, head circumference, length Z-scores).
  • Longitudinal mixed-effects models used to compare growth patterns across exposure and treatment groups.

Main Results:

  • Infants with NOWS showed decreased Z-scores for weight, length, and head circumference from birth to discharge.
  • Polysubstance exposure was associated with decreased length and head circumference Z-scores.
  • Short-acting opioid exposure correlated with improved weight Z-scores near discharge; clonidine adjunct therapy also improved weight trends.
  • Male infants exhibited lower weight and length Z-scores at Day 28 compared to females.

Conclusions:

  • Infants with NOWS requiring pharmacologic treatment experience diminished inpatient growth.
  • Prenatal polysubstance exposure poses a significant risk for poorer growth outcomes in NOWS infants.
  • Growth trajectories vary based on opioid exposure type, with potential benefits from short-acting opioid exposure and adjunct clonidine.

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
251
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
192
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
552
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
706
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
179